Trials / Terminated
TerminatedNCT01460654
Testosterone and Alendronate in Hypogonadal Men
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- Male
- Age
- 60 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
This study will investigate the hypothesis that the combination of testosterone replacement and alendronate will improve bone density and parameters of bone quality more than either medication alone in older men with low testosterone levels and low bone density.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Testosterone | Testosterone Gel (Fortesta) 40mg daily. |
| DRUG | Alendronate | Alendronate (Fosamax) 70mg every week. |
| DRUG | Placebo Alendronate | A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group. |
| DRUG | Placebo Testosterone | Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group. |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2014-05-01
- Completion
- 2014-12-01
- First posted
- 2011-10-27
- Last updated
- 2023-10-12
- Results posted
- 2023-10-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01460654. Inclusion in this directory is not an endorsement.